scholarly journals An injectable in situ gel with cubic and hexagonal nanostructures for local treatment of chronic periodontitis

Drug Delivery ◽  
2017 ◽  
Vol 24 (1) ◽  
pp. 1148-1158 ◽  
Author(s):  
Liling Mei ◽  
Xintian Huang ◽  
Yecheng Xie ◽  
Jintian Chen ◽  
Ying Huang ◽  
...  
2014 ◽  
Vol 15 (4) ◽  
pp. 1021-1028 ◽  
Author(s):  
Abeer Ahmed Kassem ◽  
Fatma Ahmed Ismail ◽  
Vivian Fahim Naggar ◽  
Elsayed Aboulmagd

Author(s):  
Vikas V. Gaikwad ◽  
Abasaheb B. Patil ◽  
Madhuri V. Gaikwad

Scaffolds are used for drug delivery in tissue engineering as this system is a highly porous structure to allow tissue growth.  Although several tissues in the body can regenerate, other tissue such as heart muscles and nerves lack regeneration in adults. However, these can be regenerated by supplying the cells generated using tissue engineering from outside. For instance, in many heart diseases, there is need for heart valve transplantation and unfortunately, within 10 years of initial valve replacement, 50–60% of patients will experience prosthesis associated problems requiring reoperation. This could be avoided by transplantation of heart muscle cells that can regenerate. Delivery of these cells to the respective tissues is not an easy task and this could be done with the help of scaffolds. In situ gel forming scaffolds can also be used for the bone and cartilage regeneration. They can be injected anywhere and can take the shape of a tissue defect, avoiding the need for patient specific scaffold prefabrication and they also have other advantages. Scaffolds are prepared by biodegradable material that result in minimal immune and inflammatory response. Some of the very important issues regarding scaffolds as drug delivery systems is reviewed in this article.


2021 ◽  
Vol 28 (4) ◽  
Author(s):  
Jitti Niyompanich ◽  
Piyachat Chuysinuan ◽  
Prasit Pavasant ◽  
Pitt Supaphol

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Ralee Spooner ◽  
Kris M. Weigel ◽  
Peter L. Harrison ◽  
KyuLim Lee ◽  
Gerard A. Cangelosi ◽  
...  

2019 ◽  
Author(s):  
Gregor Serša

Electroporation has several biomedical and industrial applications. The biomedical applications are in the field of drug or gene delivery. Electrochemotherapy utilizes electroporation for the increased delivery of cytotoxic drugs like bleomycin or cisplatin into tumors. The use of electrochemotherapy has spread throughout Europe for the treatment of cutaneous tumors or metastases. It is in the NICE guidelines and is becoming standard ablative technique in treatment of cancer. The technological advancements have also enabled the use of electrochemotherapy for the treatment of deep seated tumors, such as soft tissue or liver tumors. Clinical studies demonstrate good effectiveness on fibrosarcomas, colorectal liver metastases and hepatocellular carcinoma. However, electrochemotherapy is a local treatment that also induces moderate local immune response. This so called “in situ vaccination” induced by electrochemotherapy can be exploited in combined treatment with immune checkpoint inhibitors or electrogene therapy with immunostimulating effect. Therefore, gene electrotransfer of plasmid coding for interleukin 12 (IL-12), in combination with electrochemotherapy could result in transformation of electrochemotherapy from local into systemic treatment. This is also of our current interest, and we are undertaking steps to bring this idea from preclinical into clinical testing.


Sign in / Sign up

Export Citation Format

Share Document